A new multicentre Italian study has revealed that nearly a third of patients with triple-negative breast cancer (TNBC) who developed metastatic recurrence did not begin early first-line systemic anticancer therapy (SACT) within 90 days. The research, published in Breast Cancer Research and Treatment, links this failure to start treatment with sharply poorer survival and identifies several clinical characteristics associated with attrition.
Key findings and survival impact
The investigators followed 209 patients originally treated with neoadjuvant chemo-immunotherapy, of whom 54 developed metastatic disease during a median follow-up of 24 months. Among those 54, 17 patients (32.7%) experienced what the authors term early first-line SACT attrition—defined as not initiating SACT within 90 days of documented recurrence.
Outcomes differed markedly between those who started therapy and those who did not. Median overall survival (OS) from the point of metastatic recurrence was 3.4 months in the attrition group compared with 12.4 months in patients who received first-line treatment—an interval that underlines the clinical consequences of failing to commence systemic therapy.
Which patients were most at risk?
Statistical analysis, including multivariable logistic regression, highlighted several independent factors associated with early therapeutic attrition. These included a shorter disease-free interval, evidence of programmed death-ligand 1 (PD-L1) positivity and the presence of central nervous system (CNS) metastases.
- Shorter disease-free interval: patients who did not start treatment had a median disease-free interval of 7.4 months versus 14.3 months for those who did (P = 0.011).
- PD-L1 positivity: more common in the attrition cohort (64.7%).
- CNS metastases: observed in 41.2% of those who did not initiate first-line therapy.
"Attrition of early first-line systemic anticancer therapy (SACT) for patients with triple-negative breast cancer (TNBC) represents a meaningful gap in the care continuum and warrants improved surveillance and multidisciplinary management strategies."
Numbers at a glance
| Measure | Value |
|---|---|
| Patients in initial cohort | 209 |
| Patients with metastatic recurrence | 54 |
| Early SACT attrition | 17 (32.7%) |
| Median OS — attrition group | 3.4 months |
| Median OS — treated group | 12.4 months |
Clinical and policy implications
The findings expose a significant shortfall in the continuum of care for a particularly aggressive breast cancer subtype. TNBC lacks the hormonal targets that guide some other breast-cancer treatments, and while advances such as immunotherapy have improved options, this study shows that a notable share of patients who relapse do not receive early systemic therapy—a situation associated with very limited survival.
Several practical explanations could underpin the attrition observed here: rapid clinical deterioration after recurrence, the burden of CNS disease, or logistical and access barriers to rapid reassessment and initiation of treatment. The association with PD-L1 positivity is notable because such patients are often considered for immunotherapy combinations; higher PD-L1 prevalence in the attrition group may reflect disease biology or selection effects in this cohort.
For UK clinicians and health services, the study signals the need for vigilant follow-up pathways after neoadjuvant chemo-immunotherapy and for mechanisms to expedite assessment and treatment at relapse. Multidisciplinary teams should also consider the specific risks posed by CNS involvement and the potential need for rapid neurosurgical, radiotherapeutic or palliative interventions that could allow systemic therapy to proceed.
Finally, the stark survival difference between treated and untreated patients emphasises that improving timely access to first-line SACT could be an actionable lever to reduce mortality in this high-risk group. Further research should explore the barriers to initiation—clinical, logistical and patient-centred—and test interventions to close this care gap.
While the study is retrospective and limited to centres in Italy, its message is broadly applicable: without prompt and coordinated response after recurrence, some patients with TNBC face extremely poor prognoses. Health systems that wish to improve outcomes for this subgroup will need to address attrition proactively.
